Literature DB >> 762585

Regional impairment of cerebral oxidative metabolism in Parkinson's disease.

G L Lenzi, T Jones, J L Reid, S Moss.   

Abstract

Twenty-two patients affected by idiopathic Parkinsonism were studied using the oxygen-15 inhalation technique. The production of labelled metabolic water was found to be decreased in the parietal cerebral cortex, indicating an impairment in oxidative metabolism. This metabolic defect was localised mainly to the parietal cortex of the affected hemispheres; in non-affected hemispheres of patients presenting with unilateral Parkinsonism, the uptake was normal. In contrast, regional blood flow was not significantly altered. It is possible that this metabolic impairment is caused by chronic deafferentation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762585      PMCID: PMC490159          DOI: 10.1136/jnnp.42.1.59

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Local glucose utilization in acute focal cerebral ischemia: local dysmetabolism and diaschisis.

Authors:  M D Ginsberg; M Reivich; A Giandomenico; J H Greenberg
Journal:  Neurology       Date:  1977-11       Impact factor: 9.910

2.  Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose.

Authors:  M Reivich; D Kuhl; A Wolf; J Greenberg; M Phelps; T Ido; V Casella; J Fowler; B Gallagher; E Hoffman; A Alavi; L Sokoloff
Journal:  Acta Neurol Scand Suppl       Date:  1977

3.  Control of movement in Parkinson's disease.

Authors:  R W Angel; W Alston; J R Higgins
Journal:  Brain       Date:  1970       Impact factor: 13.501

4.  Non-invasive regional study of chronic cerebrovascular disorders using the oxygen-15 inhalation technique.

Authors:  G L Lenzi; T Jones; C G McKenzie; S Moss
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-01       Impact factor: 10.154

5.  The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man.

Authors:  T Jones; D A Chesler; M M Ter-Pogossian
Journal:  Br J Radiol       Date:  1976-04       Impact factor: 3.039

6.  Study of regional cerebral metabolism and blood flow relationships in man using the method of continuously inhaling oxygen-15 and oxygen-15 labelled carbon dioxide.

Authors:  G L Lenzi; T Jones; C G McKenzie; P D Buckingham; J C Clark; S Moss
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-01       Impact factor: 10.154

  6 in total
  10 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

2.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

3.  Cerebral glucose utilization in Parkinson's disease.

Authors:  R Sandyk; M A Gillman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-05       Impact factor: 10.154

4.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.

Authors:  S J Wang; R S Liu; H C Liu; K N Lin; D E Shan; K K Liao; J L Fuh; L S Lee
Journal:  Eur J Nucl Med       Date:  1993-04

5.  6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys.

Authors:  D J Doudet; H Miyake; R T Finn; C A McLellan; T G Aigner; R Q Wan; H R Adams; R M Cohen
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

6.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease.

Authors:  D Rougemont; J C Baron; P Collard; P Bustany; D Comar; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

7.  Three-dimensional surface display of brain perfusion with 123I-IMP in Parkinson's disease.

Authors:  H Tachibana; K Kawabata; Y Tomino; M Sugita; M Fukuchi
Journal:  Neuroradiology       Date:  1994-05       Impact factor: 2.804

8.  Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study.

Authors:  M T Hu; S D Taylor-Robinson; K R Chaudhuri; J D Bell; R G Morris; C Clough; D J Brooks; N Turjanski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

Review 9.  Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.

Authors:  Santiago Perez-Lloret; Francisco J Barrantes
Journal:  NPJ Parkinsons Dis       Date:  2016-02-18

10.  Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences.

Authors:  Domenico Sergi; Justine Renaud; Nicola Simola; Maria-Grazia Martinoli
Journal:  Front Aging Neurosci       Date:  2019-11-08       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.